Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-19
2010-10-26
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S393000, C514S338000, C514S275000, C514S322000, C514S378000, C514S254060, C514S364000, C548S306100, C544S131000, C544S139000, C546S199000
Reexamination Certificate
active
07820659
ABSTRACT:
The present invention discloses novel compounds of Formula I: (I) having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.
REFERENCES:
patent: 2008/0207691 (2008-08-01), Aicher et al.
patent: 2008/0214621 (2008-09-01), Aicher et al.
patent: 2008/0275043 (2008-11-01), Aicher et al.
patent: 2009/0069326 (2009-03-01), Allen et al.
patent: 2009/0088430 (2009-04-01), Wallace et al.
patent: 2009/0099180 (2009-04-01), Mabry et al.
patent: 2009/0099182 (2009-04-01), Li et al.
patent: 2009/0111800 (2009-04-01), Aicher et al.
patent: 2009/0111809 (2009-04-01), Bush et al.
patent: 2009/0156571 (2009-06-01), Aicher et al.
patent: 2009/0239911 (2009-09-01), Wallace et al.
patent: 2009/0264650 (2009-10-01), Yamashita et al.
patent: 2009/0275613 (2009-11-01), Li et al.
patent: 1864971 (2007-12-01), None
patent: WO 2004/056744 (2004-07-01), None
patent: WO 2005/108360 (2005-11-01), None
patent: WO 2005/108361 (2005-11-01), None
patent: WO 2006/040329 (2006-04-01), None
patent: WO 2006/049952 (2006-05-01), None
patent: WO 2006/053024 (2006-05-01), None
patent: WO 2006/068991 (2006-06-01), None
patent: WO 2006/068992 (2006-06-01), None
patent: WO 2006/104280 (2006-10-01), None
patent: WO 2007/084314 (2007-07-01), None
patent: WO 2007/124254 (2007-11-01), None
patent: WO 2007/124337 (2007-11-01), None
patent: WO 2007/127688 (2007-11-01), None
patent: WO 2007/127693 (2007-11-01), None
patent: WO 2007/127704 (2007-11-01), None
patent: WO 2007/127726 (2007-11-01), None
patent: WO 2007/127763 (2007-11-01), None
patent: WO 2007/127765 (2007-11-01), None
patent: WO 2007/127901 (2007-11-01), None
patent: WO 2008/157752 (2008-12-01), None
Yeh et al.: Discovery of orally active butyrolactam 11 β-HSD1 inhibitors, Bioorganic & Medicinal Chemistry Letters, Nov. 1, 2006, 16(21), pp. 5555-5560.
Schuster, Daniela et al.: The Discovery of New 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors by Common Feature Pharmacophore Modeling and Virtual Screening, J. Medicinal Chemistry, 2006, 49, pp. 3454-3466.
Konno et al.: Electrolytic Partial Fluorination of Organic Compounds. 6. Highly Regioselective Eletrochemical Monofluorination of Aliphatic Nitrogen-Containing Heterocycles, Tetrahedron Letters, 1992, vol. 33, No. 46, pp. 7017-7020.
Guenther Rebecca Lynn Rezac
Mabry Thomas Edward
Saeed Ashraf
Snyder Nancy June
Wallace Owen Brendan
Anderson Rebecca L
Eli Lilly and Company
Wood Dan L.
LandOfFree
Cyclohexylimidiazole lactam derivatives as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclohexylimidiazole lactam derivatives as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclohexylimidiazole lactam derivatives as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4227346